Jefferies Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Jefferies Group’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150,000	Closed	-$4M	–	1978
2021 Q3	$4M	Buy	+150,000	New	+$4.03M	0.03%	504
2021 Q1	–	Sell	-112,500	Closed	-$2.83M	–	1977
2020 Q4	$2.83M	Buy	+112,500	New	+$2.42M	0.02%	602
2019 Q4	–	Sell	-140,200	Closed	-$3.85M	–	2971
2019 Q3	$3.85M	Buy	140,200 +1,800	+1%	+$53.3K	0.03%	663
2019 Q2	$4.58M	Buy	+138,400	New	+$4.74M	0.03%	512
2017 Q3	–	Sell	-32,500	Closed	-$1.4M	–	2601
2017 Q2	$1.4M	Sell	32,500 -29,700	-48%	-$1.06M	0.01%	1123
2017 Q1	$1.95M	Buy	+62,200	New	+$1.67M	0.01%	928
2015 Q2	–	Sell	-10,000	Closed	-$121K	–	3488
2015 Q1	$121K	Buy	+10,000	New	+$94.5K	﹤0.01%	1846
2013 Q4	–	Sell	-14,700	Closed	-$108K	–	2208
2013 Q3	$108K	Buy	+14,700	New	+$98.7K	﹤0.01%	1706

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Jefferies Group's SUPN Position: Q4 2021 in Review

Jefferies Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 100 shares — an estimated $2.67K sold.

Jefferies Group first reported a position in SUPN in Q2 2014 and held it in 14 quarters. The position peaked at $4.42M in Q3 2014. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

Jefferies Group reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Jefferies Group sold 100 Supernus Pharmaceuticals shares in Q4 2021, an estimated $2.67K.
Jefferies Group first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 14 quarters.
Jefferies Group's Supernus Pharmaceuticals position peaked at $4.42M in Q3 2014.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.